Portal Vein ThrombosisNCT07473375
Indicators Affecting PVT Recanalization
An observational study of Portal Vein Thrombosis and Cirrhosis, run by Shanghai Zhongshan Hospital at 1 site in China.
Trial summary
This is a retrospective-prospective study conducted at Zhongshan Hospital, Fudan University, to explore portal vein thrombosis (PVT) in patients with cirrhosis and gastroesophageal varices (GEV). Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Portal Vein Thrombosis, Cirrhosis, Portal Hypertension Related to Cirrhosis
- How many people
- 1,500 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2017to 31 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Adult, Older adult
Study population: This study enrolled adult patients with cirrhosis and confirmed gastroesophageal varices who presented to Zhongshan Hospital, Fudan University, and were diagnosed with portal vein thrombosis (PVT)upon admission.
Who may be able to join
- diagnosed as cirrhosis and confirmed gastroesophageal varices by endoscopy;
- all patients were diagnosed as PVT by CTA at admission.
Who cannot join
- patients with hepatocellular carcinoma;
- patients with extrahepatic malignancies;
- history of liver transplantation or TIPS;
- lack of information regarding anticoagulation therapy；
- those with cavernous transformation of the portal vein(CTPV) .
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Study site
Shanghai, Shanghai Municipality, 200032
Siyu Jiang, Dr., +86 15121068078, ksjsy1996926@126.com
About this study
Official title: Indicators Affecting Portal Vein Thrombosis Recanalization in Cirrhosis With Gastroesophageal Varices
This is a retrospective-prospective study conducted at Zhongshan Hospital, Fudan University, to explore portal vein thrombosis (PVT) in patients with cirrhosis and gastroesophageal varices (GEV). It aimed to provide insights into the diagnosis, follow-up, and factors influencing PVT recanalization, to help patients, families, and healthcare providers understand the disease and related clinical management.
- Conditions
- Portal Vein Thrombosis, Cirrhosis, Portal Hypertension Related to Cirrhosis, Portal Hypertension, Noncirrhotic
- Medical subject headings
- Fibrosis, Hypertension, Portal
What is being measured
The primary outcome is the main question the study is designed to answer.
PVT recanalization at 1 year
Measured: From the first abdominal imaging assessment after admission, until the occurrence of PVT recanalization at 1 year, death, or the last follow-up, whichever came first
Secondary outcomes (3)
Occurrence of all-cause death (competing event)
Measured: From the date of admission confirmation of PVT to the occurrence of death, or the last follow-up, whichever came first
PVT recanalization at 5 years
Measured: From the first abdominal imaging assessment after admission, until the occurrence of PVT recanalization at 5 year, death, or the last follow-up, whichever came first
Occurrence of non-improved PVT
defined as unchanged thrombus size, <50% thrombus reduction, or thrombus extension to new venous segments
Measured: From the date of admission confirmation of PVT to the last radiological follow-up at 1 year, or death, whichever came first
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2026
- Study start1 Jan 2017
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Portal Vein ThrombosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Zhongshan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07473375
- Sponsor's protocol ID
- CSY-PVT-anticoagulation
- Status last verified
- Mar 2026
- First submitted
- 11 Mar 2026
- Last updated
- 16 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Indicators Affecting Portal Vein Thrombosis Recanalization in Cirrhosis With Gastroesophageal Varices
- ClinicalTrials.gov ID
- NCT07473375
- Acronym / sponsor ID
- CSY-PVT-anticoagulation
- Conditions
- Portal Vein Thrombosis, Cirrhosis, Portal Hypertension Related to Cirrhosis, Portal Hypertension, Noncirrhotic
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- Shanghai Zhongshan HospitalUniversity, hospital or other
- Study start
- 1 Jan 2017 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 16 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a retrospective-prospective study conducted at Zhongshan Hospital, Fudan University, to explore portal vein thrombosis (PVT) in patients with cirrhosis and gastroesophageal varices (GEV). It aimed to provide insights into the diagnosis, follow-up, and factors influencing PVT recanalization, to help patients, families, and healthcare providers understand the disease and related clinical management.
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- This study enrolled adult patients with cirrhosis and confirmed gastroesophageal varices who presented to Zhongshan Hospital, Fudan University, and were diagnosed with portal vein thrombosis (PVT)upon admission.
Key inclusion criteria (2 listed)
- diagnosed as cirrhosis and confirmed gastroesophageal varices by endoscopy;
Key exclusion criteria (5 listed)
- patients with hepatocellular carcinoma;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
PVT recanalization at 1 year
Time frame: From the first abdominal imaging assessment after admission, until the occurrence of PVT recanalization at 1 year, death, or the last follow-up, whichever came first
3 secondary outcomes
Occurrence of all-cause death (competing event)
Time frame: From the date of admission confirmation of PVT to the occurrence of death, or the last follow-up, whichever came first
PVT recanalization at 5 years
Time frame: From the first abdominal imaging assessment after admission, until the occurrence of PVT recanalization at 5 year, death, or the last follow-up, whichever came first
Occurrence of non-improved PVT
Time frame: From the date of admission confirmation of PVT to the last radiological follow-up at 1 year, or death, whichever came first
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Portal Vein Thrombosis
Active, not recruitingObservational study
Percutaneous Portal Vein Recanalization for Refractory Portal Hypertension in Children With Non-Cirrhotic Extrahepatic Portal Vein Obstruction
Hypertension, Portal, Interventional Radiology
Not yet recruiting
Mesenteric Vein Access for OPVT-Related Recurrent Variceal Bleeding: An Ambispective Cohort
Occlusive Portal Vein Thrombosis (OPVT), Cavernous Transformation of Portal Vein
Not yet recruiting
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
Portal Vein Thrombosis, Anticoagulant Therapy
RecruitingObservational study
Freiburg TIPS Registry
Liver Cirrhosis, Portal Hypertension
Active, not recruitingObservational study
Portal Vein Thrombosis in Liver Cirrhosis: Clinical Characteristics, Radiological Patterns, and Predictors
Liver Cirrhosis, Portal Vein Thrombosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Portal Vein Thrombosis and Cirrhosis, run by Shanghai Zhongshan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Siyu Jiang, Dr. (+86-15121068078, ksjsy1996926@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PVT recanalization at 1 year (time frame: From the first abdominal imaging assessment after admission, until the occurrence of PVT recanalization at 1 year, death, or the last follow-up, whichever came first). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026; AzTrials last refreshed its copy on 27 Oct 2026.